STAGE IV RENAL CELL CANCER AJCC V8

This study tests a personalized vaccine made from a patient's own tumor proteins, combined with the immunotherapy drug pembrolizumab, for people with advanced solid tumors. The goal is to see if the combination is safe and helps the immune system fight cancer more effectively. Ab…

This study looks at whether getting standard immunotherapy in the morning (before 11 am) or afternoon (after 12 pm) changes how well it fights advanced or metastatic solid tumors. Researchers think the body's internal clock (circadian rhythm) might affect immune activity. About 1…

This early-phase trial tests whether adding a live bacteria supplement (EXL01) to standard immunotherapy (nivolumab and ipilimumab) is safe and more effective for people with metastatic kidney cancer. About 33 participants will receive either the immunotherapy alone or with the s…

This study tests whether analyzing the DNA of a kidney tumor can help doctors pick the most effective treatment for advanced or metastatic clear cell renal cell carcinoma. About 54 adults who have not had prior systemic therapy will receive either a combination of two immunothera…

This study is for people with kidney cancer that has spread to other parts of the body. It compares two standard treatments: immunotherapy drugs alone versus immunotherapy plus surgery to remove the affected kidney. The goal is to see if adding surgery helps patients live longer.…

This phase 2 trial tests whether adding a live bacteria product called CBM588 to the immunotherapy drug pembrolizumab can help prevent kidney cancer from coming back after surgery. About 62 adults with high-risk clear cell or sarcomatoid kidney cancer will receive either pembroli…

This phase 3 trial tests whether adding a live biotherapy called MO-03 to standard immunotherapy can help control advanced or metastatic clear cell renal cell carcinoma. MO-03 is designed to improve gut health, which may make immunotherapy work better. About 718 participants will…

This study tests a combination of three drugs (bevacizumab, erlotinib, and atezolizumab) in people with advanced hereditary or sporadic papillary kidney cancer. The drugs work by cutting off the tumor's blood supply, blocking cancer growth signals, and helping the immune system a…

This study tests whether adding a fiber supplement called inulin gel to standard immunotherapy drugs (ipilimumab and nivolumab) can help control advanced kidney cancer better than immunotherapy alone. About 55 adults with kidney cancer that has spread or is locally advanced will …

This study tests a combination of three drugs (cabozantinib, nivolumab, and ipilimumab) in people with rare genitourinary cancers that have spread. The goal is to see if the combination shrinks tumors better than any single drug. About 314 adults with these rare cancers are being…

This phase 2 trial tests whether adding a lab-modified virus (VSV-IFNβ-NIS) to standard immunotherapy drugs (ipilimumab and nivolumab) can shrink tumors in people with advanced or metastatic clear cell kidney cancer. The virus is designed to kill cancer cells without harming norm…

This early-phase study tests a wearable device that creates electric fields (tumor treating fields) combined with either cabozantinib or a chemo-immunotherapy pair (nab-paclitaxel and atezolizumab) in people with advanced solid tumors in the abdomen or chest. The goal is to find …

This study tests a drug called ivonescimab given before surgery for high-risk kidney cancer that hasn't spread. The drug helps the immune system attack cancer and may also block blood vessel growth to tumors. About 31 people with clear cell kidney cancer will receive the drug bef…

This study tests whether adding precise, high-dose radiation to standard immunotherapy can better control advanced kidney cancer that has spread and cannot be surgically removed. About 240 participants will receive either immunotherapy alone or immunotherapy plus radiation to the…

This study tests whether adding a freezing procedure called cryoablation to standard radiation therapy can better relieve pain from cancer that has spread to the bones. About 40 adults with certain cancers (like prostate, kidney, or melanoma) that have spread to the bone will be …

This study looks at whether giving the cancer drug nivolumab as a shot at home is as good as getting it in a clinic. It aims to reduce the time, cost, and stress of traveling for treatment. About 50 adults with various advanced cancers will try both settings and report which they…

This study tests whether giving radiation in three smaller doses (fractionated stereotactic radiosurgery) is better than the usual single large dose for people whose cancer has spread to the brain. About 269 adults with certain cancers (like lung, breast, or melanoma) will be ran…

This study collects tissue samples from people with various advanced or early-stage cancers to train a diagnostic platform called Elephas. The goal is to see how accurately it can predict whether a patient will respond to immunotherapy or chemoimmunotherapy. About 324 participant…